Tramadol Prescription over a 4-Year Period in the USA

Bigal, Luisa M; Bibeau, Kristen; Dunbar, Stephanie

doi:10.1007/s11916-019-0777-x

Cited by 39 publications

(40 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…Tramadol, a commonly used weak opioid for the treatment of pain, has been considered an analgesic alternative, since its perceived risk of serious cardiovascular and gastrointestinal adverse effects was lower than that of nonsteroidal anti‐inflammatory drugs (NSAIDs), and its risk of addiction and respiratory depression was lower than that of traditional opioids . As a result, tramadol use has been increasing rapidly worldwide over the past decades . For example, data from Truven Health Analytics MarketScan in the United States showed that prescriptions of tramadol increased by 22.8% between 2012 and 2015, and tramadol dispensing rates increased in each of the provinces in Canada, with the highest in Nova Scotia increasing from 0.50/defined daily doses (DDD) in 2007 to 2.64/DDD in 2016 …”

Section: Introductionmentioning

confidence: 99%

“…As a result, tramadol use has been increasing rapidly worldwide over the past decades . For example, data from Truven Health Analytics MarketScan in the United States showed that prescriptions of tramadol increased by 22.8% between 2012 and 2015, and tramadol dispensing rates increased in each of the provinces in Canada, with the highest in Nova Scotia increasing from 0.50/defined daily doses (DDD) in 2007 to 2.64/DDD in 2016 …”

Section: Introductionmentioning

confidence: 99%

“…(3)(4)(5) Polypharmacy is common among elderly patients due to multiple comorbidities, and some medications may intensify the risk of fracture, either through their effect on increasing fall risk and/or through an effect on bone metabolism. (6)(7)(8)(9) Tramadol, a commonly used weak opioid for the treatment of pain, (10)(11)(12)(13)(14) has been considered an analgesic alternative, since its perceived risk of serious cardiovascular and gastrointestinal adverse effects was lower than that of nonsteroidal antiinflammatory drugs (NSAIDs), (15,16) and its risk of addiction and respiratory depression was lower than that of traditional opioids. (17,18) As a result, tramadol use has been increasing rapidly worldwide over the past decades.…”

Section: Introductionmentioning

confidence: 99%

“…(17,18) As a result, tramadol use has been increasing rapidly worldwide over the past decades. (10)(11)(12)(13)(14) For example, data from Truven Health Analytics MarketScan in the United States showed that prescriptions of tramadol increased by 22.8% between 2012 and 2015, (10) and tramadol dispensing rates increased in each of the provinces in Canada, with the highest in Nova Scotia increasing from 0.50/defined daily doses (DDD) in 2007 to 2.64/DDD in 2016. (11) Nevertheless, a recently published population-based cohort study reported a significantly higher all-cause mortality rate with tramadol use than with commonly used NSAIDs among patients with osteoarthritis; (14) however, the specific mechanisms linking tramadol use to an increased risk of mortality remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Association of Tramadol Use With Risk of Hip Fracture

Wei

Lane²,

Bolster

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Several professional organizations have recommended tramadol as one of the first‐line or second‐line therapies for patients with chronic noncancer pain and its prescription has been increasing rapidly worldwide; however, the safety profile of tramadol, such as risk of fracture, remains unclear. This study aimed to examine the association of tramadol with risk of hip fracture. Among individuals age 50 years or older without a history of hip fracture, cancer, or opioid use disorder in The Health Improvement Network (THIN) database in the United Kingdom general practice (2000–2017), five sequential propensity score–matched cohort studies were assembled, ie, participants who initiated tramadol or those who initiated one of the following medications: codeine (n = 146,956) (another commonly used weak opioid), naproxen (n = 115,109) or ibuprofen (n = 107,438) (commonly used nonselective nonsteroidal anti‐inflammatory drugs [NSAIDs]), celecoxib (n = 43,130), or etoricoxib (n = 27,689) (cyclooxygenase‐2 inhibitors). The outcome was incident hip fracture over 1 year. After propensity‐score matching, the included participants had a mean age of 65.7 years and 56.9% were women. During the 1‐year follow‐up, 518 hip fracture (3.7/1000 person‐years) occurred in the tramadol cohort and 401 (2.9/1000 person‐years) occurred in the codeine cohort. Compared with codeine, hazard ratio (HR) of hip fracture for tramadol was 1.28 (95% confidence interval [CI] 1.13 to 1.46). Risk of hip fracture was also higher in the tramadol cohort than in the naproxen (2.9/1000 person‐years for tramadol, 1.7/1000 person‐years for naproxen; HR = 1.69, 95% CI 1.41 to 2.03), ibuprofen (3.4/1000 person‐years for tramadol, 2.0/1000 person‐years for ibuprofen; HR = 1.65, 95% CI 1.39 to 1.96), celecoxib (3.4/1000 person‐years for tramadol, 1.8/1000 person‐years for celecoxib; HR = 1.85, 95% CI 1.40 to 2.44), or etoricoxib (2.9/1000 person‐years for tramadol, 1.5/1000 person‐years for etoricoxib; HR = 1.96, 95% CI 1.34 to 2.87) cohort. In this population‐based cohort study, the initiation of tramadol was associated with a higher risk of hip fracture than initiation of codeine and commonly used NSAIDs, suggesting a need to revisit several guidelines on tramadol use in clinical practice. © 2020 American Society for Bone and Mineral Research.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association of Tramadol Use With Risk of Hip Fracture

Wei

Lane²,

Bolster

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

Rates of Opioid Prescriptions Obtained After Mohs Surgery

et al. 2021

View full text Add to dashboard Cite

Efficacy and Safety of Tramadol for Knee or Hip Osteoarthritis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Zhang

Xiong

et al. 2022

Arthritis Care & Research

View full text Add to dashboard Cite

Objective To examine efficacy and safety of tramadol for knee or hip osteoarthritis (OA). Methods PubMed, Embase, Cochrane Library, and Web of Science were searched up to May 2020 for randomized controlled trials (RCTs) comparing any of the following interventions: tramadol 100 mg/day, 200 mg/day, and 300 mg/day, and placebo for knee or hip OA. Pain and function were measured at or near 12 weeks for efficacy. Gastrointestinal, cardiovascular, and central nervous system (CNS) adverse events (AEs), and withdrawals were measured for safety. Bayesian network meta‐analysis was conducted. Results Six RCTs (3,611 participants) were included. Tramadol 100 mg/day (standardized mean difference [SMD] –0.16 [95% confidence interval (95% CI) –0.34, 0.00]), 200 mg/day (SMD –0.21 [95% CI –0.37, –0.06]), and 300 mg/day (SMD –0.30 [95% CI –0.48, –0.14]) were statistically more effective than placebo in pain relief, but only tramadol 300 mg/day was better than placebo in functional improvement (SMD –0.24 [95% CI –0.47, –0.03]). Tramadol 100 mg/day (relative risk [RR] 2.29 [95% credible interval (CrI) 1.22, 4.25]), 200 mg/day (RR 4.35 [95% CrI 2.31, 8.01]), and 300 mg/day (RR 6.02 [95% CrI 3.22, 11.1]) involved a higher risk of gastrointestinal AEs. Similarly, tramadol 100–300 mg/day showed a higher risk of CNS AEs and withdrawals. However, the risk of cardiovascular AEs remained unclear. Conclusion Only tramadol 300 mg/day showed minimal improvement in pain and function but with increasing AEs compared with placebo. Tramadol may not be sufficiently recommended for knee or hip OA based on the presented evidence, especially in patients with the risk of gastrointestinal and CNS AEs.

show abstract

Tramadol Prescription over a 4-Year Period in the USA

Cited by 39 publications

References 56 publications

Association of Tramadol Use With Risk of Hip Fracture

Association of Tramadol Use With Risk of Hip Fracture

Rates of Opioid Prescriptions Obtained After Mohs Surgery

Efficacy and Safety of Tramadol for Knee or Hip Osteoarthritis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About